
Renal Cell Carcinoma
Latest News

Latest Videos

CME Content
More News

Michael Serzan, MD, discusses what a community oncologist should know about the phase 2 ARCITECT trial for patients with clear cell renal cell carcinoma.

Jaime Merchan, MD, discusses findings from an analysis presented at the 2024 ASCO Meeting.

During a Case-Based Roundtable® event, Sumanta Kumar Pal, MD, discussed regimens for recurrent metastatic clear cell renal cell carcinoma including lenvatinib plus everolimus, belzutifan, and investigational cell therapy and bispecific agents in the second article of a 2-part series.

Manmeet Ahluwalia, MD, MBA, FASCO, discusses the takeaways from a study which examined the impact of various therapies, including combination treatments, for patients with metastatic renal cell carcinoma.

The combination therapy showed consistent benefits across various subgroups, including those with poor-risk disease and higher PD-L1 expression.

During a Case-Based Roundtable® event, Stephanie A. Berg, DO, moderated a discussion on the impact of adverse events and dosing approaches on treatment of metastatic renal cell carcinoma.

Pending FDA review, TLX250-CDx awaits consideration following the successful outcomes of the phase 3 ZIRCON trial in clear cell renal cell carcinoma.

Lenvatinib plus pembrolizumab delivered a significant benefit in time to disease progression in all organs vs sunitinib in advanced renal cell carcinoma.

A retrospective analysis of the phase 3 IMmotion010 trial suggests that KIM-1 levels might hold promise as a biomarker in renal cell carcinoma.

Lenvatinib in combination with pembrolizumab yielded a greater clinical benefit rate compared with sunitinib in advanced clear cell renal cell carcinoma, regardless of patient biomarker subtype.

CD8-positive, PD-1-positive, TIM3-negative, and LAG3-negative tumor infiltrating lymphocytes did not serve as a biomarker of improved clinical outcomes of nivolumab plus ipilimumab in metastatic ccRCC.

Retrospective data from the International Metastatic Renal Cell Carcinoma Database Consortium showed limited response rates in patients treated with tyrosine kinase inhibitors who received prior lenvatinib.

The small molecule inhibitor selectively targeting HIF-2α DFF332 shows promising preliminary activity and favorable safety in patients with advanced clear cell renal carcinoma.

During a Case-Based Roundtable® event, Sumanta Kumar Pal, MD, discussed long-term outcomes of the TIVO-3 trial in patients with metastatic clear cell renal cell carcinoma in the first article of a 2-part series.

In an interview with Targeted Oncology, Regina Barragan-Carrillo, MD, discussed the background and findings from a study comparing patients who underwent thymectomy and nephrectomy.

The expert panel concludes with insights on the treatment of patients with renal cell carcinoma who progress following adjuvant therapy.

During a Case-Based Roundtable® event, Sumanta K. Pal, MD, moderated a discussion on quality of life data and experiences with dose discontinuation of frontline combination therapy for patients with renal cell carcinoma.

Nazli Dizman, MD, discusses her research on adherence to the American Society of Clinical Oncology Language of Respect Guidelines among patients with renal cell carcinoma.

During a Case-Based Roundtable® event, Ulka Vaishampayan, MBBS, discussed the safety and quality-of-life data for ipilimumab plus nivolumab in patients with advanced renal cell carcinoma in the second article of a 2-part series.

FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
The FDA is considering a subcutaneous nivolumab formulation for various solid tumors based on promising data from the phase 3 CheckMate -67T trial. A target action date has been set for December 29, 2024.

Following a review of the LITESPARK-005 trial, experts on renal cell carcinoma discuss the potential role of belzutifan in the treatment algorithm.

During a Case-Based Roundtable® event, Shilpa Gupta, MD, led a discussion on the combination of immunotherapy and tyrosine kinase inhibitors for patients with advanced renal cell carcinoma in the second article of a 2-part series.

During a Case-Based Roundtable® Chandler H. Park, MD, led a discussion on the considerations physicians have when deciding on their treatment approach in the third line for patients with advanced renal cell carcinoma in the first article of a 2-part series.





























